Insulin Lispro
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Insulin Lispro: Autoimmune oophoritis
One-Sentence Summary
Insulin lispro is a rapid-acting insulin analogue, originally used to treat type 1 and type 2 diabetes mellitus, including diabetic ketoacidosis. The TxGNN model predicts it may be effective for autoimmune oophoritis, but this is a model prediction only, with 0 clinical trials and 0 publications supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Autoimmune oophoritis |
| TxGNN Prediction Score | 0.9978 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, insulin lispro is a rapid-acting human insulin analogue. Its efficacy in diabetes is well established, but it has no known immunomodulatory action relevant to ovarian autoimmunity.
The most plausible explanation for the prediction is a shared autoimmune context. Autoimmune oophoritis often occurs within polyglandular autoimmune syndromes that include type 1 diabetes. This is an association between diseases, not a therapeutic mechanism, so the link is unsupported by any evidence compiled for this report.
Other high-scoring predictions (ranks 2 to 10) show similar patterns:
- Comorbidity-driven signals: thiamine-responsive dysfunction syndrome, classic stiff person syndrome and focal stiff limb syndrome. Insulin would treat the coexisting diabetes only, not the underlying disease.
- Likely false positives: drug-induced localized lipodystrophy, pressure-induced localized lipoatrophy and idiopathic localized lipodystrophy. Insulin injections are themselves a recognised cause of localised lipodystrophy.
- Hormone replacement: pancreatic agenesis. Insulin replacement is standard care, but it falls under the existing diabetes indication and is not a novel repurposing.
- Biological hypothesis only: opsismodysplasia (INPPL1/SHIP2, a negative regulator of insulin signalling). The direction and clinical relevance of exogenous insulin are unknown.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for autoimmune oophoritis.
For context, the only publication retrieved across the top 10 predictions concerns pancreatic agenesis (rank 7) and is indirect:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 12150359 | 2002 | Review | J Am Pharm Assoc | General review of insulin therapy in type 2 diabetes and practical aspects of starting it; does not address pancreatic agenesis directly |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 11645X | Humalog U200 Kwikpen | Injection (human analogue), pre-filled pen, 200 units per mL, 3 mL, pack of 5 | Not available in the compiled data |
Safety Considerations
- Drug Interactions: 100 interactions were identified in total; the 20 retrieved are mostly Moderate, with a few Minor. The main ones are:
- Other glucose-lowering agents (additive hypoglycaemia risk or altered glycaemic control): metformin, alogliptin and albiglutide.
- Sympathomimetics and beta-agonists (may reduce glycaemic control): epinephrine, salbutamol, formoterol, phenylephrine and pseudoephedrine.
- Beta-blockers (may mask hypoglycaemia symptoms): acebutolol.
- Corticosteroids (may raise blood glucose): hydrocortisone, plus the Minor topical hydrocortisone and alclometasone.
- Hormonal agents: estradiol, ethinylestradiol and levonorgestrel.
- Others: acetazolamide, hydrochlorothiazide, doxycycline, alpelisib and ethanol.
Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score (L5), with no trials or publications. The likely link is a shared autoimmune context with type 1 diabetes, and insulin lispro has no known mechanism against ovarian autoimmunity. Several other top predictions are comorbidity artefacts or likely false positives, such as insulin-induced lipodystrophy.
To proceed, the following is needed:
- Mechanism of action data and a plausible mechanistic rationale for autoimmune oophoritis
- A systematic literature search for any link between insulin therapy and autoimmune oophoritis
- Product Information (PI) warnings and contraindications for the Australian product
- Confirmation of the approved indication text for the ARTG entry
- Assessment of whether any benefit would simply be management of coexisting diabetes rather than a true new indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.